Clinical Trial

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

Study acronym: AVAIL
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-03-16; most recent amendment 2025-03-12.
Status change: Not Yet Recruiting → Recruiting 2021-04-05
Trial Details
NCT Number NCT04807868
Lead Sponsor AdventHealth Translational Research Institute
Collaborators: BPGbio
Conditions Non-Alcoholic Fatty Liver Disease
Enrollment 1,250 participants
Start Date 2021-04-22
Primary Completion 2025-12 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-03-13